Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABMSCT in Type 2 Diabetes
NCT02662400Phase 3Completed
- Sponsor
- Post Graduate Institute of Medical Education and Research
- Start
- Jan 2016
- Primary completion
- Oct 2016
- Modality
- Stem Cell Therapies
01
Overview
Phase 3, open-label, single-arm trial of autologous bone marrow-derived mononuclear cell in type 2 diabetes mellitus (T2DM), sponsored by Post Graduate Institute of Medical Education and Research. Primary endpoint: Improvement in insulin sensitivity after stem cell transplantation at 6 months. Started Jan 2016; status: completed.
02
Drugs
autologous bone marrow-derived mononuclear cell
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02662400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02662400.